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incidence
Malignant pleural mesothelioma (MPM) is a rare tumor. The
incidence is 1.25/100 000 in Great Britain and 1.1/100 000
in Germany. Within the next 20 years the incidence is estimated
to double in many countries. Exposure to asbestos is a well-
established etiological factor for MPM, with occupational
exposure having been documented in 70–80% of those affected.
diagnosis
Patients typically present with shortness of breath due to
pleural effusion or chest pain in a more advanced stage. The
diagnosis is usually suggested by imaging studies (unilateral
pleural thickening; pleural effusion). An occupational history
must be obtained.
Cytological examination of the effusion can be diagnostic,
but often shows equivocal results. Therefore, histology is the
gold standard. Video-assisted thoracoscopy or open pleural
biopsy in a fused pleural space may be needed to provide
sufficient material for accurate histological diagnosis. There are
three main histological types (epithelial, sarcomatous and
mixed) with 60% being epithelial.
Recent data suggest the possible contribution of serum
mesothelin-related proteins and osteopontin as useful markers
to support the diagnosis of mesothelioma, although the precise
role of these markers is yet to be defined.
staging and risk assessment
Accurate initial staging is essential to provide both prognostic
information and guidance on the most appropriate therapeutic
options. Clinical staging is based on a CT scan of the chest.
However, the conversion of such images into TNM stages is
often inconclusive. Mediastinoscopy and video-assisted
thoracoscopy may be useful in determining stage. The
international staging system for MPM emphasizes the extent of
disease post surgery in a traditional TNM system and stratifies
patients into similar prognostic categories as shown in Table 1.
The Cancer and Leukemia Group B and the European
Organization for Research and Treatment of Cancer prognostic
scores may be used. They include performance status, age,
histological type, weight loss and white blood count.
MPM rarely metastasizes to distant sites but most patients
present with locally advanced disease. The use of PET scan to
rule out extra thoracic metastasis is under investigation and
findings seem promising.
treatment
surgery
Different surgical procedures have been tested with varying
degrees of success.
Extra-pleural pneumonectomy (EPP) with resection of the
hemi-diaphragm and the pericardium en bloc has the potential
to be a radical treatment and this approach is generally
Table 1.
Stage TNM Comments
Ia T1a N0 M0 Primary tumor limited to ipsilateral parietal pleura
Ib T1b N0 M0 As stage Ia plus focal involvement of visceral pleura
II T2 N0 M0 As stage Ia or Ib plus confluent involvement of
diaphragm or visceral pleura or involvement
of the lung
III any T3 M0 Locally advanced, potentially resectable tumor
any N1 M0 Ipsilateral, bronchopulmonary or hilar lymph
node involvement
any N2 M0 Subcarinal or ipsilateral mediastinal lymph
node involvement
IV any T4 Locally advanced technically unresectable tumor
any N3 Contralateral mediastinal, internal mammary, and
ipsilateral or contralateral supraclavicular lymph
node involvement
any M1 Distant metastases
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combined with chemotherapy and/or adjuvant radiotherapy.
Surgery, the appropriateness of which is still under
consideration, should only be performed on selected patients
by experienced thoracic surgeons in the context of
a multidisciplinary team [III, A]. Selection criteria for EPP
include good ECOG performance status, early-stage disease
without mediastinal lymph node involvement, epithelial
histology and adequate pulmonary function to withstand
a pneumonectomy. Pleurectomy/decortication may be
indicated in early stages or when EPP would leave macroscopic
tumor behind.
Local palliative procedures to control pleural effusion include
parietal pleurectomy or talc pleurodesis.
radiotherapy
The use of hemithoracic radiotherapy is limited because of the
severe side-effects of irradiation of the underlying lung.
Conventional radiotherapy doses can be delivered locally as
a palliative measure for pain management. Modern
radiotherapy techniques allow for delivering high-dose
radiotherapy in an attempt to improve local control after EPP.
Prophylactic radiotherapy to reduce the incidence of port
metastases is controversial and not routinely applied.
chemotherapy
Platinum analogs, doxorubicin and some antimetabolites
(raltitrexed, pemetrexed) have shown modest single-agent
activity [III, B].
The combinations of both pemetrexed/cisplatin and
raltitrexed/cisplatin have been shown to improve survival as
well as lung function and symptom control in comparison with
cisplatin alone in randomized trials [II, A].
In a phase III trial examining second-line pemetrexed versus
best supportive care, a longer time to disease progression was
seen in the chemotherapy arm with no difference in overall
survival.
If EPP is planned, neoadjuvant or adjuvant chemotherapy
should be considered.
response evaluation
Response evaluation using CT scan is recommended after two
to three chemotherapy cycles and the modified RECIST criteria
should be applied.
follow-up
Follow-up consists of clinical evaluation with particular attention
to symptoms or chest wall recurrence and chest CT as needed.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the expert authors and the
ESMO faculty.
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